Pharmacogenomic (PGx) testing is a relatively recent innovation in care and has brought with it the hope of utilizing genetic information to better tailor medical interventions.
While the widespread use of PGx testing poses a significant potential benefit to the health system, our understanding of the cost-effectiveness of PGx testing is still maturing.
This whitepaper, An Economic Evaluation of Pharmacogenomic Testing, covers current knowledge surrounding PGx testing with regard to cost-effectiveness and highlights where evidence clearly supports its use.
Key Takeaways:
Simply fill out the form to access the whitepaper »